- Companies
- Cloudbreak Pharma
Cloudbreak Pharma Valuation Multiples
Cloudbreak Pharma is valued at $140M as of November 2026. In the last fiscal year, Cloudbreak Pharma EBITDA was ($68M).
Cloudbreak Pharma Overview
About Cloudbreak Pharma
Cloudbreak Pharma Inc is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to the development of novel and differentiated treatments. The company’s focus is on Meibomian Gland Dysfunction Associated Dry Eye Disease, Pterygium, Pinguecula, Glaucoma Filtration Surgery, Wet Age-Related Macular Degeneration, and Myopia Progression. Its drugs in pipeline include CBT-001, CBT-004, CBT-006, CBT-007, CBT-009, and CBT-011.
Founded
2020
HQ
Employees
51
Website
Financials (Last FY)
EV
$102M
Valuation Multiples
Start free trialCloudbreak Pharma Financials
Cloudbreak Pharma reported last fiscal year revenue of - and negative EBITDA of ($68M).
In the same fiscal year, Cloudbreak Pharma generated ($68M) in EBITDA losses and had net loss of ($68M).
Cloudbreak Pharma P&L
In the most recent fiscal year, Cloudbreak Pharma reported revenue of - and EBITDA of ($68M).
Cloudbreak Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Cloudbreak Pharma Stock Performance
Cloudbreak Pharma has current market cap of $140M, and enterprise value of $102M.
Market Cap Evolution
Cloudbreak Pharma's stock price is $0.15.
Cloudbreak Pharma has an EPS (earnings per share) of $-0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $140M | 0.0% | - | - | - | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCloudbreak Pharma Valuation Multiples
Cloudbreak Pharma trades at (1.5x) EV/EBITDA.
Cloudbreak Pharma Financial Valuation Multiples
As of November 19, 2026, Cloudbreak Pharma has market cap of $140M and EV of $102M.
Cloudbreak Pharma has a P/E ratio of (2.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cloudbreak Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Cloudbreak Pharma Operational KPIs
Cloudbreak Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Cloudbreak Pharma Competitors
Cloudbreak Pharma competitors include Biosyent, Invivyd, Humacyte, Sutro Biopharma, Starpharma, PolyPid, Scancell, Biomm, IMBiologics and Atrium Therapeutics.
Most Cloudbreak Pharma public comparables operate across Biopharmaceuticals, Contract Research & Manufacturing and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $30M | $8M | 4.5x | 2.8x | 16.0x | 11.4x | |||
| $53M | ($50M) | 0.4x | 0.4x | (0.4x) | (0.1x) | |||
| $2M | ($25M) | 69.1x | 37.0x | (5.7x) | - | |||
| $102M | ($151M) | 0.1x | 0.2x | (0.1x) | - | |||
| $8M | ($5M) | 16.2x | 14.2x | (27.2x) | (33.0x) | |||
| - | ($32M) | - | 23.1x | (3.8x) | - | |||
| - | ($24M) | - | 150.8x | (6.7x) | (5.3x) | |||
| $47M | $329K | 3.3x | - | 468.3x | - | |||
This data is available for Pro users. Sign up to see all Cloudbreak Pharma competitors and their valuation data. Start Free Trial | ||||||||
Cloudbreak Pharma VC Funding History
Before going public, Cloudbreak Pharma raised $171M in total equity funding, across 3 rounds.
Cloudbreak Pharma Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cloudbreak Pharma
| When was Cloudbreak Pharma founded? | Cloudbreak Pharma was founded in 2020. |
| Where is Cloudbreak Pharma headquartered? | Cloudbreak Pharma is headquartered in United States. |
| How many employees does Cloudbreak Pharma have? | As of today, Cloudbreak Pharma has over 51 employees. |
| Is Cloudbreak Pharma publicly listed? | Yes, Cloudbreak Pharma is a public company listed on HKEX. |
| What is the stock symbol of Cloudbreak Pharma? | Cloudbreak Pharma trades under 02592 ticker. |
| When did Cloudbreak Pharma go public? | Cloudbreak Pharma went public in 2025. |
| Who are competitors of Cloudbreak Pharma? | Cloudbreak Pharma main competitors include Biosyent, Invivyd, Humacyte, Sutro Biopharma, Starpharma, PolyPid, Scancell, Biomm, IMBiologics, Atrium Therapeutics. |
| What is the current market cap of Cloudbreak Pharma? | Cloudbreak Pharma's current market cap is $140M. |
| Is Cloudbreak Pharma profitable? | No, Cloudbreak Pharma is not profitable. |
| How many companies Cloudbreak Pharma has acquired to date? | Cloudbreak Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Cloudbreak Pharma has invested to date? | Cloudbreak Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Cloudbreak Pharma
Lists including Cloudbreak Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




